Matrix metalloproteinase-2, -9 and tissue inhibitor metalloproteinase-1 in patients with hypertension before and after doxazosin therapy

被引:1
|
作者
Derosa G. [1 ,4 ]
Cicero A.F.G. [2 ]
D'Angelo A. [1 ]
Tinelli C. [3 ]
Ciccarelli L. [1 ]
Piccinni M.N. [1 ]
Pricolo F. [1 ]
Salvadeo S. [1 ]
Montagna L. [1 ]
Fogari E. [1 ]
Gravina A. [1 ]
Ferrari I. [1 ]
Galli S. [1 ]
Paniga S. [1 ]
Fogari R. [1 ]
机构
[1] Department of Internal Medicine and Therapeutics, University of Pavia, Pavia
[2] 'D. Campanacci' Department of Clinical Medicine and Applied Biotechnology, 'G. Descovich' Atherosclerosis Study Center, University of Bologna, Bologna
[3] Biometric Unit, IRCCS Policlinico S. Matteo, Pavia
[4] Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Piazzale C. Golgi
关键词
Hypertensive Patient; Felodipine; Antihypertensive Treatment; Doxazosin; Fast Plasma Insulin;
D O I
10.2165/00151642-200613020-00002
中图分类号
学科分类号
摘要
Background: There are conflicting data in the literature regarding both the expression pattern of the vascular metalloproteinase (MMP) system and its tissue inhibitors (TIMPs) in human hypertension and the effect of antihypertensive drugs in modifying the MMP/TIMP system. This study was designed to test the hypothesis that MMP-2, MMP-9 and TIMP-1 are altered in hypertension reflecting alterations in extracellular matrix turnover. Moreover, the aim of the study was to assess whether chronic antihypertensive treatment with doxazosin would normalise these alterations. Materials and results: We measured plasma levels and activities of MMP-2, MMP-9 and TIMP-1 in 44 hypertensive patients before and after 4 months of doxazosin treatment. MMP-2 levels and activity were significantly lower in the hypertensive group after treatment (p < 0.0001) compared with respective values before treatment. Significant decrease was also observed for MMP-9 level and activity (p < 0.0001) and for TIMP-1 (p < 0.0001) in hypertensive patients after antihypertensive treatment. Conclusions: Plasma levels and activities of MMP-2, MMP-9 and TIMP-1 are decreased in hypertensive patients after treatment compared with respective values before treatment. This may demonstrate that antihypertensive drugs modify the MMP/TIMP system, contributing to the mechanisms of vascular remodelling. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:47 / 52
页数:5
相关论文
共 50 条
  • [31] Effect of all-trans retinoic acid on renal expressions of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rats with glomerulosclerosis
    Qin, Yuan-Han
    Lei, Feng-Ying
    Hu, Peng
    Pei, Juan
    Feng, Zhen-bo
    Pang, Yu-Sheng
    [J]. PEDIATRIC NEPHROLOGY, 2009, 24 (08) : 1477 - 1486
  • [32] Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans
    Dellalibera-Joviliano, Renata
    Jacob-Ferreira, Anna L. B.
    Joviliano, Edwaldo Edner
    Tanus-Santos, Jose E.
    Evora, Paulo R. B.
    [J]. VASCULAR MEDICINE, 2012, 17 (02) : 73 - 78
  • [33] Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis
    Wang, Ying-De
    Yan, Pei-Yun
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (37) : 6050 - 6053
  • [34] Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure
    Gerlach, Raquel F.
    Tanus-Santos, Jose E.
    [J]. AMERICAN HEART JOURNAL, 2006, 152 (01)
  • [35] Relationship of osteopontin, matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1, C-reactive protein and target organ damage in patients with essential hypertension
    Xu, Tingyan
    Li, Yanxiu
    Wu, Shengnan
    Niu, Wenqun
    Zhu, Dingliang
    Gao, Pingjin
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 137 : S34 - S34
  • [36] Plasma levels of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 correlate with disease stage and survival in colorectal cancer patients
    Waas, ET
    Hendriks, T
    Lomme, RMLM
    Wobbes, T
    [J]. DISEASES OF THE COLON & RECTUM, 2005, 48 (04) : 700 - 710
  • [38] DEGRADATION OF VITRONECTIN BY MATRIX METALLOPROTEINASE-1, METALLOPROTEINASE-2, METALLOPROTEINASE-3, METALLOPROTEINASE-7 AND METALLOPROTEINASE-9
    IMAI, K
    SHIKATA, H
    OKADA, Y
    [J]. FEBS LETTERS, 1995, 369 (2-3): : 249 - 251
  • [39] Increases in matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 mRNA after cerebral contusion and depolarisation
    von Gertten, C
    Holmin, S
    Mathiesen, T
    Nordqvist, ACS
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 73 (06) : 803 - 810
  • [40] Association of matrix metalloproteinase-1, matrix metalloproteinase-9, tissue inhibitor of matrix metalloproteinase-1, and interleukin-6 with epicardial and myocardial perfusion
    Tanindi, Asli
    Sahinarslan, Asife
    Elbeg, Sehri
    Cemri, Mustafa
    [J]. CORONARY ARTERY DISEASE, 2011, 22 (04) : 253 - 258